Merck Sharp + Dohme Corp.

Msd R&d (china) Co., Ltd.

Alejandro Crespo

Dong-Ming Shen

Christopher Joseph Sinz

Ping Liu

Liping Wang

Jiaqiang Cai

Xiaoxing Du

Weiguo Quan

Rongqiang Liu

Hong Shen

Peter J Sinclair

Zhicai Wu

Richard Thomas Beresis

John S Debenham

Anthony K Ogawa

Robert J DeVita

Christina B Madsen-Duggan

Yuguang Wang

Ping Lan

Changhe Qi

Troy McCracken

Deodialsingh Guiadeen

John Qiang Tan

Zhongxiang Sun

Rudrajit Mal

Ellen K Vande Bunte

Min Shu

William K Hagmann

Michael P Dwyer

Bin Hu

John A McCauley

Barbara A Pio

Kun Liu

Michael W Miller

Dong Xiao

Peter D Williams

Deping Wang

Sherman Tim Waddell

Duane E DeMong

Gregori J Morriello

Helen Y Chen

Harry R Chobanian

Yan Guo

Xin-Jie Chu

Kartik M Keertikar

Linda Brockunier

Christopher W Plummer

M Katharine Holloway

Christopher James Bungard

Shimin Xu

Lehua Chang

David Jonathan Bennett

Tao Ji

Vincent Colandrea

Bin Zhong

Catherine M Wiscount

Shankaran Kothandaraman

Meng Yang

H Marie Loughran

Matthew John Clements

Jonathan E Wilson

Dann Parker

Jesse J Manikowski

Zack Zhiqiang Guo

Karen M Marcantonio

Byron Dubois

Haitang Li

Joshua G McCoy

Matthew J H Clements

Jurgen Schulz

Johnathan E Wilson

Michael Miller

Linda L Brockunier

Duane E Demong

Troy Mccracken

The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. 

Triazolyl pyrimidinone compounds as PDE2 inhibitors

Pyrazolyl pyrimidinone compounds as PDE2 inhibitors

The present invention concerns compounds of formula I or a pharmaceutically acceptable salt thereof which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. 

Inhibitors of HIF prolyl hydroxylase

The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. 

Piperazine derivatives as HIV protease inhibitors

The present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. 

The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. 

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic bicyclic compounds

The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.

Mineralocorticoid receptor antagonists

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and the pharmaceutical compositions which comprise compounds of the formula (I) are disclosed too. 

Growing community of inventors

Edison, NJ, United States of America

Alejandro Crespo